Investigator-Initiated Study of Imipramine Hydrochloride and Lomustine in Recurrent Glioblastoma
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.
Glioblastoma
DRUG: Lomustine|DRUG: Imipramine Hydrochloride
Progression Free Survival, 6 months
This study is designed as a single center, prospective, open label, single-arm therapeutic trial with both surgical and non-surgical cohorts.